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Effectiveness of cyproheptadine in the management
of delayed vomiting after cisplatin-based chemotherapy
and the assessment of the influence of cyproheptadine on quality of life
Piotr Koralewski, Iwona Nawara, Maria Marczak-Zi´tkiewicz, Wojciech Cegielski
I n t r o d u c t i o n. Nausea and vomiting belong to the most frequently occurring side effects of chemotherapy, significantly wor-
sening the quality of life of patients receiving cytostatics. The problem of treatment of delayed emesis occurring after admini-
stration of cytostatics with the highest emetic potential remains unsolved.
Cyproheptadine is a non-specific blocker of serotonine and histamine receptors with a proven antiallergic, antiulcerous and
appetite stimulating activity. Its non-specific influence on central and peripheral serotonine receptors suggests the possible in-
fluence of this drug on emesis in patients.
The aim of this study was to assess the effectiveness of cyproheptadine in the management of delayed vomiting after the cispla-
tin-based multi-drug chemotherapy and to assess the influence of cyproheptadine on the quality of life of patients receiving che-
motherapy.
M a t e r i a l  a n d  m e t h o d s. The study was prospective and randomized. Sixty chemotherapy-naïve patients (44 women and
16 men), for whom at least three courses of cisplatine-based chemotherapy were planned, were entered. All patients received
standard antiemetic treatment (ondansetron /8 mg iv/ or tropisetron /5 mg iv / with dexamethazone /8 mg iv / during the 1st day
of treatment and also during the 2nd day when symptoms of nausea and vomiting ECOG grade 2 persisted). The patients be-
longing to one group additionally received cyproheptadine (Peritol – EGISTM) 12 mg per day for subsequent courses. To com-
pare differences between studied groups according to intensity of nausea and vomiting, non-parametric Mann-Whitney’s and
chi-square tests were applied. The remaining parameters (body weight, level of physical and psychological functioning) were
analyzed with the use of t-Student test and F Snedecor’s test.
R e s u l t s. The study did not confirm the hypothesis about the influence of cyprohepatdine on the frequency and intensity of
delayed vomiting after chemotherapy. However a positive influence of cyproheptadine administration on the occurrence of de-
layed nausea, body weight gain and quality of life in the aspect of physical functioning was observed.
Ocena skutecznoÊci cyproheptadyny
w leczeniu wymiotów opóênionych, towarzyszàcych chemioterapii,
z udzia∏em cisplatyny i jej wp∏yw na jakoÊç ˝ycia chorych poddanych chemioterapii
W s t ´ p. Wymioty i nudnoÊci sà najcz´Êciej wyst´pujàcymi niepo˝àdanymi objawami chemioterapii, sà te˝ objawami istot-
nie pogarszajàcymi jakoÊç ˝ycia chorych poddanych leczeniu cytostatykami. Problem leczenia wymiotów opóênionych,
wyst´pujàcych po zastosowaniu cytostatyków nale˝àcych do grupy o najsilniejszym dzia∏aniu emetogennym, pozostaje cià-
gle otwarty.
Cyproheptadyna jest niespecyficznym blokerem receptorów serotoninowych i histaminowych o udowodnionym dzia∏aniu
w leczeniu alergii, przeciwwrzodowym i zwi´kszajàcym ∏aknienie. Niespecyficzne dzia∏anie cyproheptadyny na receptory se-
rotoninowe centralne i obwodowe sugeruje mo˝liwoÊç wp∏ywu tego leku na wyst´powanie u pacjentów nudnoÊci i wymio-
tów.
Celem pracy by∏y ocena skutecznoÊci cyproheptadyny w opanowywaniu nudnoÊci i wymiotów opóênionych w grupie chorych
poddanych chemioterapii wielolekowej z udzia∏em cisplatyny oraz ocena wp∏ywu leczenia z udzia∏em cyproheptadyny na ja-
koÊç ˝ycia chorych poddanych leczeniu chemicznemu.
M a t e r i a ∏  k l i n i c z n y  i m e t o d y k a  b a d a n i a. DoÊwiadczenie mia∏o charakter prospektywnie zaplanowanej, randomi-
zowanej próby klinicznej. Do badania zakwalifikowano 60 chorych (44 kobiety i 16 m´˝czyzn), którzy otrzymali trzy pe∏ne se-
rie chemioterapii wielolekowej, opartej o cisplatyn´. Wszyscy chorzy otrzymywali standardowe leczenie przeciwwymiotne
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Introduction
Nausea and vomiting belong to the most frequently occur-
ring side effects of chemotherapy, significantly worsening
the quality of life of patients receiving treatment with cy-
tostatics.[1, 2]. Cisplatine belongs to cytostatics with the
highest emetic potential. The problem of acute emesis
was solved by applying the strategies of concomitant ad-
ministration of 5-HT3 receptors antagonists together with
dexamethasone, on the contrary the problem of treat-
ment of delayed emesis remains unsolved. [3, 4]. Delayed
emesis are defined as emesis occurring 24 hours after
chemotherapy. About 20–50% of patients treated with
cisplatine still suffer from this adverse reaction.
The underlying cause of delayed emesis is not clear.
The influence of cytostatics or its metabolite on the gut or
central nervous system and so called rebound effect, oc-
curring after the activity of antiemetics stops, are listed as
possible causes [5, 6, 7]. It can be also suspected, that
neurotransmitters and receptors other than 5-HT3 take
part in pathogenesis of delayed emesis.
Cyproheptadine is a non-specific blocker of serotoni-
ne and histamine receptors with a proven antiallergic,
antiulcerous and appetite stimulating activity [8]. Its non-
-specific influence on central and peripheral serotonine
receptors suggests the possible influence of this drug on
emesis in patients. At the same time its 5-HT2 receptor
antagonist effect decreases the secretion of hydrochloric
acid in stomach. The sedating effect – through blockade
of histamine (H3) receptors – can also have a favorable
result in decreasing nausea and vomiting (benzodiaze-
pins and chlorpromazine are often used in antiemetic
procedures). On account of what mentioned above it se-
ems justifiable to conclude that administration of the
drug with a multiple mechanism of action, blocking cen-
tral and peripheral receptors can lead to a better tole-
rance of chemotherapy.
The end points of this study were:
– the assessment of effectiveness of cyproheptadine
in the management of delayed vomiting after the ci-
splatin-based multi-drug chemotherapy,
– the assessment of influence of cyproheptadine on the
quality of life of patients treated with chemotherapy.
Material and methods
The study was prospective and randomized. 60 chemotherapy-
-naïve patients (44 women and 16 men), for whom at least three
courses of cisplatine-based chemotherapy were planned, were
entered.
The population of patients was divided into two groups
A and B with same number of patients. The randomization was
based on the date of birth: even number – group A, odd number
– group B. All patients received cisplatine-based multi-drug
chemotherapy and identical antiemetic treatment (ondansetron
/8 mg iv/ or tropisetron /5 mg iv/ with dexamethazone /8 mg iv /
during the 1st day of treatment and also during the 2nd day when
symptoms of nausea and vomiting ECOG grade 2 persisted).
The patients belonging to group A additionally received cypro-
heptadine (Peritol – EGISTM) 12 mg per day for subsequent
courses.
Mean age in group A was 54.9 years (34–73 years) and in
group B – 57.2 years (41–72 years). Table I summarizes the in-
formation about diagnosis and applied treatment for all patients
entered in the study. Frequency and intensity of nausea and vo-
miting were analyzed with the patients’ diaries of side effects of
chemotherapy. Each course was assessed separately with ECOG
scale.
drogà do˝ylnà tj. ondansetron (8 mg) lub tropisetron (5 mg) z deksametazonem (8 mg) w pierwszym dniu leczenia i ewentu-
alnie w dniu kolejnym w przypadku utrzymywania si´ nudnoÊci i wymiotów drugiego stopnia wg ECOG, a jedna z grup do-
datkowo otrzymywa∏a pomi´dzy kolejnymi seriami leczenia cyproheptadyn´ w dawce 12 mg/dob´. Metody statystyczne.
W celu porównania ró˝nic pomiedzy badanymi grupami w zakresie nat´˝enia nudnoÊci i wymiotów u˝yto testów nieparame-
trycznych Manna-Whitneya i chi-kwadrat. Do analizy statystycznej pozosta∏ych cech (masa cia∏a, poziom funkcjonowania psy-
chologicznego i fizycznego) wykorzystano test t-Studenta oraz test F Snedecora.
W y n i k i .  Badanie nie potwierdzi∏o hipotezy o wp∏ywie cyproheptadyny na cz´stoÊç i nasilenie wymiotów opóênionych po che-
mioterapii. Wykazano natomiast pozytywny wp∏yw tego rodzaju leczenia na zmniejszenie nasilenia nudnoÊci, przyrost wagi cia-
∏a, a tak˝e samopoczucie fizyczne, rozumiane jako jeden z wymiarów jakoÊci ˝ycia chorych.
Key words: cyproheptadyna, nudnoÊci i wymioty opóênione, chemioterapia oparta o cisplatyn´, jakoÊç ˝ycia
S∏owa kluczowe: cyproheptadine, delayed emesis, cisplatin-based chemotherapy, quality of life
Tab. I. Clinical material according to diagnosis and treatment procedures
(in brackets number of patients in group A+B)
Diagnosis Treatment
PC GEM+DDP 5FU+DDP BEP Together
Ovarian cancer 44 (22 + 22) 44 (22 + 22)
Lung cancer 8 (4 + 4) 8 (4 + 4)
Head and neck cancers 7 (3 + 4) 7 (3 + 4)
Testicular cancer 1 (1 + 0) 1 (1 + 0)
Together 44 (22 + 22) 8 (4 +4) 7 (3 + 4) 1 (1 + 0) 60 (30 + 30)
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The quality of life of patients was evaluated according to
Rotterdam Symptom Checklist, applied to check the level of
psychological and physical functioning disturbances [9].
The control measurements of body weight were also per-
formed during the study.
The observation of frequency and intensity of nausea and
vomiting applied to all three courses of chemotherapy so three
records in patients’ diaries were obtained (Ist after 1st course, IInd
after 2nd etc), while the quality of life was assessed before the tre-
atment (point „0”) and then after each course (4 measurements).
S t a t i s t i c a l  a n a l y s i s
For the following parameters statistical analysis was perfor-
med: vomiting, nausea, level of physical and psychological func-
tioning and body weight.
Intensity of nausea and vomiting were ordinal variables
of integer values. Non-parametric Mann-Whitney’s and chi-squ-
are tests were applied to compare differences between studied
groups.
Body weight is a continuous interval parameter. Level of
physical and psychological functioning as a sum of multiple fac-
tors can be assumed to be (according to Central Limit The-
orem) variables with near-normal distribution.
t-Student test for non-related variables was applied in order
to establish significance of differences of mean values of parame-
ters in a given measurement between groups A and B. Signifi-
cance was assumed for P values <0.05.
In order to establish significance of differences of means in
one group (A or B) but in different time-points, one-way
ANOVA for related variables was applied (F Snedecor’s test).
Usage of both tests was justified by results of Ko∏mogorow-
-Smirnow’ test of normal distribution of analyzed data.
Results
Statistical analysis of the data from patients’ diaries com-
paring the number of observed side effects i.e. nausea
and vomiting in the period from the 2nd till the 9th day
after chemotherapy did not reveal any significant differen-
ces between both groups in case of vomiting. Calculated
statistics value (Mann-Whitney’s test) equals –1.38 with
p value of 0.17.
On the other hand significant influence of cypro-
heptadine administration on the occurrence of delayed
nausea was observed. Value of chi-square statistics equals
4.4, what with one degree of freedom means statistical
significance on the level of 0.05 (p=0.036).
From qualitative analysis of cards of observation it
can be concluded that cyproheptadine is well tolerated by
patients treated with cytostatics.
The results of quality of life measurements obtained
with the Rotterdam Symptom Checklist indicate that both
the physical and psychological well-being remained more
stable in patients from the group A (receiving cyprohepta-
dine) than in the group B (low values of standard devia-
tion).
The patients from group A rated their physical func-
tioning better during subsequent courses of chemothera-
py. No difference was observed however, according to
psychological functioning of patients in both groups.
Tables II and III show the results of comparison of
mean values indicating the level of functioning distur-
bances in psychological and physical aspects.
The increase of body weight measured during the treat-
ment is presented on Figure 1.
Tab. II. The comparison of mean values of levels of psychological functioning disturbances in groups A i B and in subsequent points of evaluation
(0-before chemotherapy, I – 1st course, II – 2nd course, III – 3rd course)
Point of evaluation Group A Group B Results of t-Student test for groups A and B
Mean Standard Mean Standard Value of No. of degree p
deviation Deviation t-statistics of freedom
0 13.70 4.15 14.13 4.26 -0.399 58 >0.05
I 11.60 2.62 11.80 3.38 -0.256 58 >0.05
II 10.90 2.17 10.93 3.10 -0.048 58 >0.05
III 10.50 1.81 11.40 3.27 -1.320 58 >0.05
Value of F statistics Value of F statistics 9.879 12.855
in ANOVA between 
measurements
O,I,II,III Number of degree 3 3
of freedom
p <0.001 <0.001
Value of F statistics Value of F statistics 2.592 1.918
in ANOVA between 
measurements
I,II,III Number of degree 2 2
of freedom
p >0.05 >0.05
Fig. 1. Change of mean body weight of patients
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The mean body weight of patients from group B is
higher in every checked time-point than of patients from
group A. Those differences though are not statistically
significant due to relatively high value of standard devia-
tion of this variable in both groups.
In group A the mean body weight systematically in-
creases during subsequent measurements. In group B the-
re is a small drop between points I and II, and then mini-
mal improvement.
As a result of analysis of variance for related data it
was shown that in group A body weight gain between se-
parate measurements is significant with p=0.05 (F test va-
lue = 3.381) while group B was lacking such relationship
(respective value of F = 0.095).
Summary
Broad and non-typical spectrum of activity of cyprohepta-
dine allowed the hypothesis that this drug can be effecti-
vely administered to treat emesis occurring after 24 hours
after chemotherapy. The paper by Andersen et al. [10] in-
dicating the effectiveness of cyproheptadine in the tre-
atment of cyclic vomiting syndrome in children can indi-
rectly justify this assumption.
The influence on final results of such parameters as
sex, age and possible tendency to alcohol abuse was elimi-
nated by the construction of the study.
Statistical description of collected clinical data did
not confirm the expected influence of the drug on fre-
quency and intensity of delayed vomiting. Significant de-
crease of nausea, confirming the activity of the drug, was
observed however, the effect was not as good as expected.
It can not be excluded, that rising the dose of cyprohepta-
dine can enhance its effectiveness, but still there is not
enough clinical data to support this thesis.
Relatively low price of the drug allows its prolon-
ged administration. This encouraged authors to perform
the analysis on its influence on quality of life of patients
treated with chemotherapy. The attempt to translate sub-
jective qualitative data into the language of statistics was
undertaken. Finally, it was confirmed with statistical signi-
ficance, that the differences in the aspect of physical func-
tioning in favor of group treated with cyproheptadine are
observed after three months of use of the drug. The stable
tendency to body weight gain in patients receiving this
drug supports this observation. Differences on the level of
psychological functioning were not significant.
However it is understood, that the weak point of
this study is the lack of double-blind method with the use
of placebo, it still seems reasonable to perform further
studies on cyproheptadine in concomitant therapy for
patients treated with anticancer chemotherapy. Continu-
ous improvement of quality of life of patients suffering
from neoplastic disease should form a superior goal. It is
also advisable to search for new, better methods for eva-
luating the quality of life itself, one of the most complex
and complicated issues in medicine.
Conclusions
1. The administration of cyproheptadine at the dose 12
mg/day between subsequent courses of cisplatine based
chemotherapy does not influence occurrence of de-
layed vomiting.
2. Administration of the drug decreases frequency and in-
tensity of delayed nausea.
Tab. III. The comparison of mean values of physical well being disturbances in group A and B and in subsequent points of evaluation
(0-before chemotherapy, I – 1st course, II – 2nd course, III – 3rd course)
Point of evaluation Group A Group B Results of t-Student test for groups A and B
Mean Standard Mean Standard Value of No. of degree p
deviation Deviation t-statistics of freedom
0 25.60 4.69 26.23 5.32 -0.489 58 >0.05
I 25.83 3.39 28.10 6.42 -1.636 58 >0.05
II 24.87 4.60 27.47 6.87 -1.723 58 >0.05
III 24.53 3.61 27.00 5.41 -2.077 58 <0.05
Value of F statistics Value of F statistics 1.028 1.289
in ANOVA between 
measurements
O,I,II,III Number of degree 3 3
of freedom
p >0.05 >0.05
Value of F statistics Value of F statistics 1.455 0.949
in ANOVA between 
measurements
I,II,III Number of degree 2 2
of freedom
p >0.05 >0.05
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3. The quality of life in physical aspect of patients rece-
iving cyproheptadine is better than in the control gro-
up.
4. Existing observations justify the introduction of new
studies on application of cyproheptadine as an adjunc-
tive therapy for patients treated with anticancer che-
motherapy.
Piotr Koralewski M.D. Ph.D
Chemotherapy Dept. Rydygier Memorial Hospital
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